Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (368)	1/8/2005 7:36:13 PM
From: Natashya_Fatale	Read Replies (2) of 946

I think xyotax is a slam dunk replacement for paclitaxel. It's likely going to be approved as a replacement for Taxol in 1st line multimode therapy, ie., one of the platins (carbo or cisplatin) + xyotax. The Phase I dose escalation in lung cancer in San Antonio has everybody in oncology glued to their seats. At the present rate, it looks like much larger doses of paclitaxel/taxol can be run in on the 1st cycle than ever before, with much less toxicity. The Phase I in San Antonio at IDD is supposedly yielding excellent results as a monotherapy. Time will tell. Last I heard, they were dosing patients at 135mg/m2 on a weekly cycle. One of my mentors is shepherding a few Phase 1s at IDD and he echoes their praise of xyotax. OK, do I get a free xyotax sweatshirt now? Nicki

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next